HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 2 (2005), Issue 5 (May)

1. CD8+ T cell responses to human immunodeficiency viruses type 2 (HIV-2) and type 1 (HIV-1) gag proteins are distinguishable by magnitude and breadth but not cellular phenotype.
   Eur J Immunol, 35(5): 1445-53. [Abstract] [Full-text]
2. The binding affinity of double-stranded RNA motifs to HIV-1 Tat protein affects transactivation and the neutralizing capacity of anti-Tat antibodies elicited after intranasal immunization.
   Eur J Immunol, 35(5): 1521-9. [Abstract] [Full-text]
3. Discovery and characterization of highly immunogenic and broadly recognized mimics of the HIV-1 CTL epitope Gag77-85.
   Eur J Immunol, 35(5): 1428-37. [Abstract] [Full-text]
4. Unique characteristics of HIV-1 Vif expression.
   Microbes Infect, 7(3): 385-90. [Abstract] [Full-text]
5. Different susceptibility of human immunodeficiency virus type 1 to Env gp41-derived synthetic peptides corresponding to the C-terminal heptad repeat region.
   Microbes Infect, 7(3): 356-64. [Abstract] [Full-text]
6. Antiretroviral resistance mutations in human immunodeficiency virus type 1 infected patients enrolled in genotype testing at the Central Public Health Laboratory, São Paulo, Brazil: preliminary results.
   Mem Inst Oswaldo Cruz, 100(1): 97-102. [Abstract] [Full-text]
7. Is human immunodeficiency virus/acquired immunodeficiency syndrome decreasing among Brazilian injection drug users? Recent findings and how to interpret them.
   Mem Inst Oswaldo Cruz, 100(1): 91-6. [Abstract] [Full-text]
8. Human immunodeficiency virus type 1 neutralization by plasma from B or F genotype infected individuals.
   Mem Inst Oswaldo Cruz, 100(1): 85-9. [Abstract] [Full-text]
9. The human immunodeficiency virus preventive vaccine research at the French National Agency for acquired immunodeficiency syndrome research.
   Mem Inst Oswaldo Cruz, 100(1): 79-84. [Abstract] [Full-text]
10. Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.
    Mem Inst Oswaldo Cruz, 100(1): 73-8. [Abstract] [Full-text]
11. Immune response in cervical dysplasia induced by human papillomavirus: the influence of human immunodeficiency virus-1 co-infection -- review.
    Mem Inst Oswaldo Cruz, 100(1): 1-12. [Abstract] [Full-text]
12. Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects.
    J Allergy Clin Immunol, 115(5): 1081-7. [Abstract] [Full-text]
13. Antigenic conservation and immunogenicity of the HIV coreceptor binding site.
    J Exp Med, 201(9): 1407-19. [Abstract] [Full-text]
14. p53-A pro-apoptotic signal transducer involved in AIDS.
    Biochem Biophys Res Commun, 331(3): 701-6. [Abstract] [Full-text]
15. Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase.
    Nat Cell Biol, 7(5): 493-500. [Abstract] [Full-text]
16. Assembly of human immunodeficiency virus precursor gag proteins.
    J Biol Chem, 280(18): 17664-70. [Abstract] [Full-text]
17. Genetic polymorphisms in CX3CR1 predict HIV-1 disease progression in children independently of CD4+ lymphocyte count and HIV-1 RNA load.
    J Infect Dis, 191(11): 1971-80. [Abstract] [Full-text]
18. Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism.
    J Infect Dis, 191(11): 1961-70. [Abstract] [Full-text]
19. Estimating HIV evolutionary pathways and the genetic barrier to drug resistance.
    J Infect Dis, 191(11): 1953-60. [Abstract] [Full-text]
20. Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor.
    Clin Immunol, 115(1): 26-32. [Abstract] [Full-text]
21. Different roles of Sp family members in HIV-1 Tat-mediated manganese superoxide dismutase suppression in hepatocellular carcinoma cells.
    DNA Cell Biol, 24(5): 299-310. [Abstract] [Full-text]
22. Coregistration of quantitative proton magnetic resonance spectroscopic imaging with neuropathological and neurophysiological analyses defines the extent of neuronal impairments in murine human immunodeficiency virus type-1 encephalitis.
    J Neurosci Res, 80(4): 562-75. [Abstract] [Full-text]
23. Drosophila melanogaster as a complementary system for studying HIV-1-related genes and proteins.
    J Neurosci Res, 80(4): 451-5. [Abstract] [Full-text]
24. Preclinical and clinical performance of the Efoora test, a rapid test for detection of human immunodeficiency virus-specific antibodies.
    J Clin Microbiol, 43(5): 2399-406. [Abstract] [Full-text]
25. Detection of acute infections during HIV testing in North Carolina.
    N Engl J Med, 352(18): 1873-83. [Abstract] [Full-text]
26. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
    Nature, 435(7038): 108-14. [Abstract] [Full-text]
27. Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy.
    Metabolism, 54(5): 561-7. [Abstract] [Full-text]
28. Predicting short-term disease progression among HIV-infected patients in Asia and the Pacific region: preliminary results from the TREAT Asia HIV Observational Database (TAHOD).
    HIV Med, 6(3): 216-23. [Abstract] [Full-text]
29. Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London.
    HIV Med, 6(3): 206-15. [Abstract] [Full-text]
30. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules.
    HIV Med, 6(3): 185-90. [Abstract] [Full-text]
31. The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
    HIV Med, 6(3): 179-84. [Abstract] [Full-text]
32. Gender difference in HIV-1 RNA viral loads.
    HIV Med, 6(3): 170-8. [Abstract] [Full-text]
33. Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients.
    HIV Med, 6(3): 164-9. [Abstract] [Full-text]
34. Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database.
    HIV Med, 6(3): 155-63. [Abstract] [Full-text]
35. The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.
    HIV Med, 6(3): 151-4. [Abstract] [Full-text]
36. Improving survival among Brazilian children with perinatally-acquired AIDS.
    Braz J Infect Dis, 8(6): 419-23. [Abstract] [Full-text]
37. Establishment of the serologic testing algorithm for recent human immunodeficiency virus (HIV) seroconversion (STARHS) strategy in the city of São Paulo, Brazil.
    Braz J Infect Dis, 8(6): 399-406. [Abstract] [Full-text]
38. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy.
    Ophthalmology, 112(5): 771-9. [Abstract] [Full-text]
39. Is there a role for plant-made vaccines in the prevention of HIV/AIDS?
    Immunol Cell Biol, 83(3): 239-47. [Abstract] [Full-text]
40. Brachial amyotrophic diplegia in a patient with human immunodeficiency virus infection: widening the spectrum of motor neuron diseases occurring with the human immunodeficiency virus.
    Arch Neurol, 62(5): 817-23. [Abstract] [Full-text]
41. Enhanced apoptotic action of trichosanthin in HIV-1 infected cells.
    Biochem Biophys Res Commun, 331(4): 1075-80. [Abstract] [Full-text]
42. CCL3L1 dose and HIV-1 susceptibility.
    Trends Mol Med, 11(5): 203-6. [Abstract] [Full-text]
43. HIV-1 trafficking to the dendritic cell-T-cell infectious synapse uses a pathway of tetraspanin sorting to the immunological synapse.
    Traffic, 6(6): 488-501. [Abstract] [Full-text]
44. Mechanism of zinc coordination by point-mutated structures of the distal CCHC binding motif of the HIV-1 NCp7 protein.
    Biochemistry, 44(19): 7315-25. [Abstract] [Full-text]
45. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization.
    Biochemistry, 44(19): 7250-8. [Abstract] [Full-text]
46. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy.
    Acta Neuropathol (Berl), 109(4): 449-55. [Abstract] [Full-text]
47. Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients.
    J Gene Med, 7(5): 552-64. [Abstract] [Full-text]
48. Multiparameter evaluation of human thymic function: interpretations and caveats.
    Clin Immunol, 115(2): 138-46. [Abstract] [Full-text]
49. Evaluation of cerebrospinal fluid uPA, PAI-1, and soluble uPAR levels in HIV-infected patients.
    J Neuroimmunol, 163(1): 190-4. [Abstract] [Full-text]
50. Neuroinflammatory responses from microglia recovered from HIV-1-infected and seronegative subjects.
    J Neuroimmunol, 163(1): 145-56. [Abstract] [Full-text]
51. Death ligand-mediated apoptosis in HIV infection.
    Rev Med Virol, 15(3): 169-78. [Abstract] [Full-text]
52. Docetaxel in anthracycline-pretreated AIDS-related Kaposi's sarcoma: a retrospective study.
    Br J Dermatol, 152(5): 1026-9. [Abstract] [Full-text]
53. Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles.
    J Virol, 79(11): 7135-45. [Abstract] [Full-text]
54. Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry.
    J Virol, 79(11): 7121-34. [Abstract] [Full-text]
55. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
    J Virol, 79(11): 7059-67. [Abstract] [Full-text]
56. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    J Virol, 79(11): 6957-68. [Abstract] [Full-text]
57. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
    J Virol, 79(11): 6909-17. [Abstract] [Full-text]
58. Effect of polypurine tract (PPT) mutations on human immunodeficiency virus type 1 replication: a virus with a completely randomized PPT retains low infectivity.
    J Virol, 79(11): 6859-67. [Abstract] [Full-text]
59. Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy.
    J Virol, 79(11): 6848-58. [Abstract] [Full-text]
60. Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.
    J Virol, 79(11): 6791-800. [Abstract] [Full-text]
61. Interaction with CD4 and antibodies to CD4-induced epitopes of the envelope gp120 from a microglial cell-adapted human immunodeficiency virus type 1 isolate.
    J Virol, 79(11): 6703-13. [Abstract] [Full-text]
62. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription.
    J Virol, 79(11): 6610-9. [Abstract] [Full-text]
63. Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing.
    Immunity, 22(5): 607-19. [Abstract] [Full-text]
64. Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth.
    Structure (Camb), 13(5): 755-68. [Abstract] [Full-text]
65. Transgene vaccination using Ulex europaeus agglutinin I (UEA-1) for targeted mucosal immunization against HIV-1 envelope.
    Vaccine, 23(29): 3836-42. [Abstract] [Full-text]
66. Identification and characterization of HIV-1-specific CD8+ T cell epitopes presented by HLA-A*2601.
    Vaccine, 23(29): 3783-90. [Abstract] [Full-text]
67. Duration of an intermittent episode of viremia.
    Bull Math Biol, 67(4): 885-900. [Abstract] [Full-text]
68. Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects.
    Bull Math Biol, 67(4): 783-813. [Abstract] [Full-text]
69. A decrease in drug resistance levels of the HIV epidemic can be bad news.
    Bull Math Biol, 67(4): 761-82. [Abstract] [Full-text]
70. RISUG (reversible inhibition of sperm under guidance)--an antimicrobial as male vas deferens implant for HIV free semen.
    Med Hypotheses, 65(1): 61-4. [Abstract] [Full-text]
71. The paradox of HIV nef function: resolution of the contradictions.
    Med Hypotheses, 65(1): 44-6. [Abstract] [Full-text]
72. HIV protease inhibitors: synthesis and activity of N-aryl-N'-hydroxyalkyl hydrazide pseudopeptides.
    Eur J Med Chem, 40(5): 445-51. [Abstract] [Full-text]
73. The RNA helicase DDX1 is involved in restricted HIV-1 Rev function in human astrocytes.
    Virology, 336(2): 299-307. [Abstract] [Full-text]
74. Natural resistance of human immunodeficiency virus type 2 to zidovudine.
    Virology, 336(2): 251-64. [Abstract] [Full-text]
75. Nef enhances c-Cbl phosphorylation in HIV-infected CD4+ T lymphocytes.
    Virology, 336(2): 219-28. [Abstract] [Full-text]
76. Thymic pathogenicity of an HIV-1 envelope is associated with increased CXCR4 binding efficiency and V5-gp41-dependent activity, but not V1/V2-associated CD4 binding efficiency and viral entry.
    Virology, 336(2): 184-97. [Abstract] [Full-text]
77. Codon volatility does not reflect selective pressure on the HIV-1 genome.
    Virology, 336(2): 137-43. [Abstract] [Full-text]
78. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression.
    J Infect Dis, 191(12): 2053-63. [Abstract] [Full-text]
79. Suppression of multidrug-resistant HIV-1 reverse transcriptase primer unblocking activity by alpha-phosphate-modified thymidine analogues.
    J Mol Biol, 349(3): 451-63. [Abstract] [Full-text]
80. Investigating HIV-1 polypurine tract geometry via targeted insertion of abasic lesions in the (-)-DNA template and (+)-RNA primer.
    J Biol Chem, 280(20): 20154-62. [Abstract] [Full-text]
81. The fusion activity of HIV-1 gp41 depends on interhelical interactions.
    J Biol Chem, 280(20): 19852-7. [Abstract] [Full-text]
82. Cost-effectiveness of a behavioral intervention for seropositive youth.
    AIDS Educ Prev, 17(2): 105-18. [Abstract] [Full-text]
83. alpha-Tocopherol as an antiretroviral therapy supplement for HIV-1-infected patients for increased lymphocyte viability.
    Clin Chem Lab Med, 43(4): 376-82. [Abstract] [Full-text]
84. Psychological distress among AIDS orphans in rural Uganda.
    Soc Sci Med, 61(3): 555-64. [Abstract] [Full-text]
85. The impact of health care providers on female sterilization among HIV-positive women in Brazil.
    Soc Sci Med, 61(3): 541-54. [Abstract] [Full-text]
86. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells.
    Proc Natl Acad Sci U S A, 102(20): 7239-44. [Abstract] [Full-text]
87. Thrombotic thrombocytopenic purpura in a patient with acquired immunodeficiency syndrome at 28 weeks gestation.
    Am J Perinatol, 22(4): 223-5. [Abstract] [Full-text]
88. A human splicing factor, SKIP, associates with P-TEFb and enhances transcription elongation by HIV-1 Tat.
    Genes Dev, 19(10): 1211-26. [Abstract] [Full-text]
89. Efficacy and tolerability of multiple drug therapy in HIV-infected children.
    J Infect, 50(5): 404-11. [Abstract] [Full-text]
90. Properties of anti-gp41 core structure antibodies, which compete with sera of HIV-1-infected patients.
    Microbes Infect, 7(4): 650-7. [Abstract] [Full-text]
91. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study.
    Arch Intern Med, 165(10): 1179-84. [Abstract] [Full-text]
92. High IL-7 plasma levels may induce and predict the emergence of HIV-1 virulent strains in pediatric infection.
    J Clin Virol, 33(3): 237-42. [Abstract] [Full-text]
93. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
    J Clin Virol, 33(3): 224-9. [Abstract] [Full-text]
94. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
    J Clin Virol, 33(3): 206-16. [Abstract] [Full-text]
95. Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy.
    J Clin Virol, 33(3): 194-200. [Abstract] [Full-text]
96. SEN virus seroprevalence in HIV positive patients: association with immunosuppression and HIV-replication.
    J Clin Virol, 33(3): 183-7. [Abstract] [Full-text]
97. Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).
    J Clin Virol, 33(2): 99-103. [Abstract] [Full-text]
98. AIDS knowledge and attitudes in Iran: results from a population-based survey in Tehran.
    Patient Educ Couns, 57(2): 199-203. [Abstract] [Full-text]
99. Mesuol, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF-kappaB pathway.
    Antiviral Res, 66(2): 137-45. [Abstract] [Full-text]
100. Highly potent anti-HIV-1 activity isolated from fermented Polygonum tinctorium Aiton.
     Antiviral Res, 66(2): 119-28. [Abstract] [Full-text]
101. HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells.
     Brain Res, 1045(1): 57-63. [Abstract] [Full-text]
102. Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanine.
     Antiviral Res, 66(2): 153-8. [Abstract] [Full-text]
103. Most DC-SIGNR transcripts at mucosal HIV transmission sites are alternatively spliced isoforms.
     Eur J Hum Genet, 13(6): 707-15. [Abstract] [Full-text]
104. Analysis of a 17-amino acid residue, virus-neutralizing microantibody.
     J Gen Virol, 86: 1791-800. [Abstract] [Full-text]
105. Neutralization sensitivity of HIV-1 Env-pseudotyped virus clones is determined by co-operativity between mutations which modulate the CD4-binding site and those that affect gp120-gp41 stability.
     Virology, 337(1): 136-48. [Abstract] [Full-text]
106. Indian primary HIV-2 isolates and relationship between V3 genotype, biological phenotype and coreceptor usage.
     Virology, 337(1): 68-75. [Abstract] [Full-text]
107. Infection of human and non-human cells by a highly fusogenic primary CD4-independent HIV-1 isolate with a truncated envelope cytoplasmic tail.
     Virology, 337(1): 30-44. [Abstract] [Full-text]
108. Improved HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma.
     J Med Virol, 76(3): 291-6. [Abstract] [Full-text]
109. Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients.
     J Med Virol, 76(3): 297-301. [Abstract] [Full-text]
110. Identification of amino acid residues in the human immunodeficiency virus type-1 reverse transcriptase tryptophan-repeat motif that are required for subunit interaction using infectious virions.
     J Mol Biol, 349(4): 673-84. [Abstract] [Full-text]
111. Uncoating of HIV-1 requires cellular activation.
     Virology, 337(1): 93-101. [Abstract] [Full-text]
112. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.
     Antimicrob Agents Chemother, 49(6): 2314-21. [Abstract] [Full-text]
113. G-protein signaling triggered by R5 human immunodeficiency virus type 1 increases virus replication efficiency in primary T lymphocytes.
     J Virol, 79(12): 7938-41. [Abstract] [Full-text]
114. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.
     J Virol, 79(12): 7933-7. [Abstract] [Full-text]
115. Disruption of human TRIM5alpha antiviral activity by nonhuman primate orthologues.
     J Virol, 79(12): 7883-8. [Abstract] [Full-text]
116. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.
     J Virol, 79(12): 7777-84. [Abstract] [Full-text]
117. Single point mutations in the zinc finger motifs of the human immunodeficiency virus type 1 nucleocapsid alter RNA binding specificities of the gag protein and enhance packaging and infectivity.
     J Virol, 79(12): 7756-67. [Abstract] [Full-text]
118. Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1.
     J Virol, 79(12): 7728-37. [Abstract] [Full-text]
119. Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.
     J Virol, 79(12): 7349-54. [Abstract] [Full-text]
120. Dendritic cell precursors are permissive to dengue virus and human immunodeficiency virus infection.
     J Virol, 79(12): 7291-9. [Abstract] [Full-text]
121. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection.
     Addiction, 100(6): 820-8. [Abstract] [Full-text]
122. HIV/AIDS health literacy in Zimbabwe--focus group findings from university students.
     Methods Inf Med, 44(2): 288-92. [Abstract] [Full-text]
123. Human retinal microglia express candidate receptors for HIV-1 infection.
     Br J Ophthalmol, 89(6): 753-7. [Abstract] [Full-text]
124. HIV exceptionalism, CD4+ cell testing, and conscientious subversion.
     J Med Ethics, 31(6): 322-6. [Abstract] [Full-text]
125. Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1.
     RNA, 11(6): 873-84. [Abstract] [Full-text]
126. Current status of gene therapy strategies to treat HIV/AIDS.
     Mol Ther, 11(6): 823-42. [Abstract] [Full-text]
127. The impact of the transmission dynamics of the HIV/AIDS epidemic on sexual behaviour: a new hypothesis to explain recent increases in risk taking-behaviour among men who have sex with men.
     Med Hypotheses, 65(2): 215-26. [Abstract] [Full-text]
128. CXCR4 and CCR5 regulation and expression patterns on T- and monocyte-macrophage cell lineages: implications for susceptibility to infection by HIV-1.
     Math Biosci, 195(1): 92-126. [Abstract] [Full-text]
129. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41.
     Biochim Biophys Acta, 1723(1): 270-81. [Abstract] [Full-text]
130. Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site.
     J Biol Chem, 280(22): 21353-7. [Abstract] [Full-text]
131. Artificial zinc finger fusions targeting Sp1-binding sites and the trans-activator-responsive element potently repress transcription and replication of HIV-1.
     J Biol Chem, 280(22): 21545-52. [Abstract] [Full-text]
132. Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics.
     Biochem Biophys Res Commun, 332(3): 831-6. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.